Evidence map›Paper›PMID 40996886›Full record

ArticleCell reports2025

Transdifferentiation of endothelial progenitor cells into rhabdomyosarcoma defined by hedgehog signaling competence.

Katherine E Gadek, Catherine J Drummond, Hongjian Jin, Matthew R Garcia, Edwin D Mathew, Grace E Adkins, Casey G Langdon, Myron Evans, Madeline B Searcy, Patrick Schreiner and 4 more

Erratum issuedAbstract read
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Katherine E GadekDepartment of Oncology, St. Jude Children's Research Hospital Memphis, Memphis TN 38105, USA.
Catherine J DrummondDepartment of Oncology, St. Jude Children's Research Hospital Memphis, Memphis TN 38105, USA.
Hongjian JinCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Matthew R GarciaDepartment of Oncology, St. Jude Children's Research Hospital Memphis, Memphis TN 38105, USA.
Edwin D MathewDepartment of Oncology, St. Jude Children's Research Hospital Memphis, Memphis TN 38105, USA.
Grace E AdkinsSt. Jude Graduate School of Biomedical Sciences, Memphis, TN 38105, USA.
Casey G LangdonDepartment of Oncology, St. Jude Children's Research Hospital Memphis, Memphis TN 38105, USA.
Myron EvansDepartment of Oncology, St. Jude Children's Research Hospital Memphis, Memphis TN 38105, USA.
Madeline B SearcySt. Jude Graduate School of Biomedical Sciences, Memphis, TN 38105, USA.
Patrick SchreinerCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Matthew MaguireDepartment of Oncology, St. Jude Children's Research Hospital Memphis, Memphis TN 38105, USA.
Jerold E RehgDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Stacey K OgdenDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Mark E HatleyDepartment of Oncology, St. Jude Children's Research Hospital Memphis, Memphis TN 38105, USA; St. Jude Graduate School of Biomedical Sciences, Memphis, TN 38105, USA. Electronic address: mark.hatley@stjude.org.

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Defining the non-myogenic origins of pediatric rhabdomyosarcomaR01CA216344 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HATLEY, MARK EDWARD · 2017 to 2021
$2.0M
Mediators Of Arrested Differentiation In Pediatric RhabdomyosarcomaR01CA251436 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HATLEY, MARK EDWARD · 2021 to 2025
$2.0M
Determining the Mechanism of Rhabdomyosarcoma Transformation from a Non-Myogenic Cell of OriginF31CA290924 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC · PI Grace Elizabeth Adkins · 2025 to 2026
$98k
NCI NIH HHS F31 CA290924NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA216344NCI NIH HHS R01 CA251436
6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma resembling developing skeletal muscle, but tumors are found in sites devoid of skeletal muscle, suggesting a non-myogenic cell of origin. We previously described an endothelial progenitor cell-derived model of RMS by activating a conditional, constitutively active Smoothened mutant (SmoM2) with aP2-Cre. We sought to further identify the endothelial progenitor cell of origin in our aP2-Cre;R26

Indexed as

Cell TransdifferentiationEndothelial Progenitor CellsHedgehog ProteinsRhabdomyosarcomaSignal TransductionAnimalsCell LineageHumansMiceSmoothened ReceptorHedgehog ProteinsSmoothened Receptorcell reprogrammingciliaCP: Cancerendothelial cellhedgehogpediatric cancerprimary ciliarhabdomyosarcomasarcomaskeletal muscletransdifferentiation

Identifiers

PMID40996886
PMCPMC12592795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.